Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Simcere Pharmaceutical Group Limited Capital/Financing Update 2020

Oct 13, 2020

48856_rns_2020-10-12_752c8bc0-b968-47d6-bb95-14291427d8f9.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant 如 閣下欲以香港中央結算（代理人）有限公司（「香港結算代理人」）的名義 登記將獲發行的香港發售股份，並直接存入中央結算及交收系統（「中央結算系統」），以寄存於 閣下的中 央結算系統投資者戶口持有人股份戶口或 閣下指定的中央結算系統參與者股份戶口，請使用本表格

This Application Form uses the same terms as defined in the prospectus of Simcere Pharmaceutical Group Limited (the “ Company ”) dated October 13, 2020 (the “ Prospectus ”).

Staple your 本申請表格使用先聲藥業集團有限公司（「 本公司 」）於2020年10月13日刊發的招股書（「 招股書 」）所界定的 payment 詞語。 here Neither this Application Form nor the Prospectus constitutes an offer to sell or the solicitation of an offer to buy any Hong Kong Offer Shares in any jurisdiction other than Hong Kong. The Hong Kong Offer Shares may 請將股款 not be offered or sold in the United States without registration or an exemption from registration under the U.S. 緊釘在此 Securities Act. 本申請表格及招股書概不構成在香港以外任何司法管轄區要約出售或游說要約購買任何香港發售股份。若 無根據美國證券法登記或豁免登記，香港發售股份不得在美國提呈發售或出售。 This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction. 在任何根據當地法例不得發送、派發或複製本申請表格及招股書的司法管轄區內概不得發送或派發或複製 （不論方式，也不論全部或部分）本申請表格及招股書。 Copies of the Prospectus, all related Application Forms and the other documents specified in the “Documents Delivered to the Registrar of Companies and Available for Inspection – Documents Delivered to the Registrar of Companies” section in Appendix VI to the Prospectus, have been registered by the Registrar of Companies in Hong Kong as required by Section 38D of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “ Stock Exchange ”), Hong Kong Securities Clearing Company Limited (“ HKSCC ”), the Securities and Futures Commission of Hong Kong (the “ SFC ”) and the Registrar of Companies of Hong Kong take no responsibility for the contents of these documents. 招股書、所有相關申請表格及招股書附錄六「送呈公司註冊處處長及備查文件－送呈公司註冊處處長文件」 一節所述其他文件已遵照香港法例第32章公司（清盤及雜項條文）條例第38D條的規定，送呈香港公司註冊 處處長登記。香港交易及結算所有限公司、香港聯合交易所有限公司（「 聯交所 」）、香港中央結算有限公司 （「 香港結算 」）、香港證券及期貨事務監察委員會（「 證監會 」）及香港公司註冊處處長對此等文件的內容概不 負責。 Simcere Pharmaceutical Group Limited 先聲藥業集團有限公司 (Incorporated in Hong Kong with limited liability) （於香港註冊成立的有限公司） Stock Code : 2096 股份代號：2096 Maximum Offer Price : HK$13.70 per Offer Share, plus brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund) 最高發售價：每股發售股份13.70港元，另加1%經紀佣金、 0.0027%證監會交易徵費及0.005%聯交所交易費 （須於申請時以港元繳足，多繳款項可予退還） You should read this Application Form in conjunction with the Prospectus, which contains further information on the application procedures. ， 一 。 招股 ~~書尚有~~ 關 ~~於~~ 申 ~~請~~ 程 ~~序的~~ 其 ~~他資料~~ 本申請表格應與招股書 併閱讀 Application Form 申請表格 To: Simcere Pharmaceutical Group Limited 致： 先聲藥業集團有限公司 Joint Sponsors 聯席保薦人 Joint Global Coordinators 聯席全球協調人 Joint Bookrunners 聯席賬簿管理人 Hong Kong Underwriters 香港包銷商

致： 先聲藥業集團有限公司 聯席保薦人 聯席全球協調人 聯席賬簿管理人 香港包銷商 申請人聲明

Applicants’ declaration

本人╱吾等同意本申請表格及招股書的條款及條件以及申請 程序。請參閱本申請表格「填交本申請表格的效用」一節。

I/We agree to the terms and conditions and application procedures in this Application Form and the Prospectus. Please refer to the “Effect of completing and submitting this Application Form” section of this Application Form.

警告：任何人士只限作出一次為其利益而進行的認購申請。 請參閱「填交本申請表格的效用」一節最後四點。

Warning: Only one application may be made for the benefit of any person. Please refer to the last four bullets of “Effect of completing and submitting this Application Form” section.

Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant 如 閣下欲以香港中央結算（代理人）有限公司（「香港結算代理人」）的名義 登記將獲發行的香港發售股份，並直接存入中央結算及交收系統（「中央結算系統」），以寄存於 閣下的中 央結算系統投資者戶口持有人股份戶口或 閣下指定的中央結算系統參與者股份戶口，請使用本表格

Signed by (all) applicant(s) (all joint applicants must sign): 由（所有）申請人簽署（所有聯名申請人必須簽署）：

For Broker use 此欄供經紀填寫 Lodged by 遞交申請的經紀 由（所有）申請人簽署（所有聯名申請人必須簽署）： Broker No. 經紀號碼 Broker’s Chop 經紀印章 Date 日期： / / D日 M月 Y年 Number of Hong Kong Offer Shares applied for (not more than Cheque/banker’s cashier order number 支票 ╱ 銀行本票號碼 13,029,000 Shares) 申請香港發售股份數目（不超過13,029,000股股份） Name of bank on which cheque/banker’s cashier order is drawn (see “How to make your application” section) 兌現支票 ╱ 銀行本 Total amount 總額 票的銀行名稱（見「申請手續」一節） HK$ 港元 Name in English (in BLOCK letters) 英文姓名╱名稱（以正楷填寫） Family name or company name 姓氏或公司名稱 Forename(s) 名字 Name in Chinese 中文姓名╱名稱 Family name or company name 姓氏或公司名稱 Forename(s) 名字 Occupation in English 職業（以英文填寫） Hong Kong Identity Card No./Passport No./Hong Kong Business Registration No. (Please delete as appropriate) 香港身份證號碼╱護 照號碼╱香港商業登記號碼（請刪除不適用者） Names of all other joint applicants in English (if any, in BLOCK letters) Hong Kong Identity Card No./Passport No./Hong Kong Business Registration No. 所有其他聯名申請人的英文姓名╱名稱（如有，以正楷填寫） of all other joint applicants (Please delete as appropriate) 的香港身份證號碼╱護照號碼╱香港商業登記號碼（請刪除不適用者）所有其他聯名申請人 1) 1) 2) 2) 3) 3) Hong Kong address in English and telephone no. (joint applicants should give the address and the telephone number of first-named applicant only in BLOCK letters) 香港地址（以英文正楷填寫）及電話號碼（聯名申請人只須填寫排名首位申請人的地址及電話號碼） Telephone No. 電話號碼 For Nominees: You will be treated as applying for your own THIS BOX MUST BE DULY COMPLETED benefit if you do not complete this section. Please provide 必須填妥此欄 an account number or identification code for each (joint) Participant I.D. of the CCASS Investor Participant or designated CCASS Participant beneficial owner. 由代名人遞交：代名人若不填寫本節，是項 中央結算系統投資者戶口持有人或指定的中央結算系統參與者的參與者編號 認購申請將視作為 閣下利益提出。請填寫每名（聯名）實 益擁有人的賬戶號碼或識別編碼。

ADDRESS LABEL 地址標貼 (Your name(s) and address in Hong Kong in BLOCK letters 請用英文正楷填寫 姓名╱名稱 及香港 地址 )

For designated CCASS Participant or Corporate CCASS Investor Participant, please also affix the company chop bearing its company name 指定的中央結算系統參與者或中央結算系統公司投資者戶口 持有人，請加蓋附有公司名稱的公司印鑑

(See paragraph 2 in the section “How to make your application”) （請參閱「申請手續」一節第2段）

For internal use 此欄供內部使用

Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant 如 閣下欲以香港中央結算（代理人）有限公司（「香港結算代理人」）的名義 登記將獲發行的香港發售股份，並直接存入中央結算及交收系統（「中央結算系統」），以寄存於 閣下的中 央結算系統投資者戶口持有人股份戶口或 閣下指定的中央結算系統參與者股份戶口，請使用本表格

  • *(1) If you are a CCASS Investor Participant, only a Hong Kong Identity Card number (if you are an individual) or a Hong Kong Business Registration number (if you are a body corporate) will be accepted for this application, please see paragraph 2 under the section “How to make your application”. 如 閣下為中央結算系統投資者戶口持有人，是項申請僅接納香港身份證號碼（如屬個別人士）或 香港商業登記號碼（如屬法人團體）；請參閱「申請手續」一節第2段。

  • (2) If you are applying through a designated CCASS Participant (other than a CCASS Investor Participant): For an individual, you must provide your Hong Kong Identity Card number or passport number. If you hold a Hong Kong Identity Card, please provide that number. If you do not hold a Hong Kong Identity Card, please provide your passport number. For a body corporate, please provide your Hong Kong Business Registration number. 如 閣下透過中央結算系統投資者戶口持有人以外的指定中央結算系統參與者提出申請：如屬個 別人士，必須填寫 閣下的香港身份證號碼或護照號碼（持有香港身份證者請填寫香港身份證號 碼，否則請填寫護照號碼）；如屬法人團體，請填寫香港商業登記號碼。

  • (3) Part of the Hong Kong Identity Card number/passport number of you or, for joint applicants, the firstnamed applicant may be printed on your refund cheque (if any). Such data will be used for checking the validity of Application Form and such data would also be transferred to a third party for such purpose and refund purpose. Your banker may require verification of your Hong Kong Identity Card number/passport number before you can cash your refund cheque. 日後如需退回申請股款，退款支票上或會印有 閣下或（如屬聯名申請人）排名首位申請人的香港 身份證號碼╱護照號碼的一部分。有關資料將用於核實申請表格的有效性，亦會轉交第三方作資 料核實和退款。銀行兌現退款支票前或會要求查證 閣下的香港身份證號碼╱護照號碼。

  • (4) If an application is made by an unlisted company and: • the principal business of that company is dealing in securities; and • you exercise statutory control over that company, then the application will be treated as being made for your benefit. 如申請人是一家非上市公司，而： • 該公司的主要業務為證券買賣；及 • 閣下可對該公司行使法定控制權， 是項申請將視作為 閣下的利益提出。

  • (5) All joint applicants must give (if they are individuals) their Hong Kong Identity Card numbers or, where applicable, passport numbers, or (if they are bodies corporate) their Hong Kong Business Registration numbers.

  • 所有聯名申請人必須提供（如屬個別人士）其香港身份證號碼或（如適用）護照號碼，或（如屬法人 團體）其香港商業登記號碼。

This page is intentionally left blank 此乃白頁 特意留空

Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant

How to make your application

  1. Use the table below to calculate how much you must pay. Your application must be for a minimum of 1,000 Hong Kong Offer Shares and in one of the numbers set out in the table, or your application will be rejected.

HongKongOffer Shares and in one of the numbers set out in the table, oryour application will be rejected.
Simcere Pharmaceutical Group Limited
(HK$13.70 per Hong Kong Offer Share)
NUMBER OF HONG KONG OFFER SHARES THAT MAY BE APPLIED FOR AND PAYMENTS
No. of
Amount
No. of
Amount
No. of
Amount
No. of
Amount
2.
3.		 Hong Kong
Offer Shares
applied for
payable
on application
HK$
Hong Kong
Offer Shares
applied for
payable
on application
HK$
Hong Kong
Offer Shares
applied for
payable
on application
HK$
Hong Kong
Offer Shares
applied for
payable
on application
HK$
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
10,000
15,000
13,838.06
27,676.11
41,514.17
55,352.22
69,190.28
83,028.33
96,866.39
110,704.44
124,542.50
138,380.55
207,570.83
20,000
25,000
30,000
35,000
40,000
45,000
50,000
60,000
70,000
80,000
90,000
276,761.10
345,951.38
415,141.65
484,331.93
553,522.20
622,712.48
691,902.75
830,283.29
968,663.84
1,107,044.39
1,245,424.94
100,000
200,000
300,000
400,000
500,000
600,000
700,000
800,000
900,000
1,000,000
2,000,000
1,383,805.49
2,767,610.98
4,151,416.47
5,535,221.96
6,919,027.45
8,302,832.94
9,686,638.43
11,070,443.92
12,454,249.41
13,838,054.90
27,676,109.80
3,000,000
4,000,000
5,000,000
6,000,000
7,000,000
8,000,000
9,000,000
10,000,000
13,029,000(1)
41,514,164.70
55,352,219.60
69,190,274.50
83,028,329.40
96,866,384.30
110,704,439.20
124,542,494.10
138,380,549.00
180,296,017.30
(1)Maximum number of Hong Kong
Offer Shares you may apply for.

You, as the applicant(s), must complete the form in English (in BLOCK letters) as indicated below and sign on the
second page of the Application Form. Only written signatures will be accepted (and not by way of personal chop).
If you are applying through a designated CCASS Participant (other than a CCASS Investor Participant):
•
the designated CCASS Participant must endorse the form with its company chop (bearing its
company name) and insert its participant I.D. in the appropriate box.
If you are applying as an individual CCASS Investor Participant:
•
the form must contain your NAME and Hong Kong I.D. Card number.
•
your participant I.D. must be inserted in the appropriate box.
If you are applying as a joint individual CCASS Investor Participant:
•
the form must contain all joint investor participants’ NAMES and the Hong Kong I.D. Card
number of all joint investor participants;
•
your participant I.D. must be inserted in the appropriate box.
If you are applying as a corporate CCASS Investor Participant:
•
the form must contain your company NAME and Hong Kong Business Registration number;
•
your participant I.D. and your company chop (bearing your company name) must be inserted in
the appropriate box.
Incorrect or omission of details of the CCASS Participant including participant I.D. and/or company
chop bearing its company name or other similar matters may render your application invalid.

Staple your cheque or banker’s cashier order to the form. Each application for the Hong Kong Offer Shares
must be accompanied by either one separate cheque or one separate banker’s cashier order. Your application
will be rejected if your cheque or banker’s cashier order does not meet all the following requirements:
The cheque must:
Banker’s cashier order must:
•
be in Hong Kong dollars;
Sample 樣版





•
not be post-dated;
•
be made payable to “BANK OF CHINA (HONG KONG) NOMINEES LIMITED –
SIMCERE PHARMACEUTICAL PUBLIC OFFER”;
•
be crossed “Account Payee Only”;
•
be drawn on your Hong Kong dollar bank
•
be issued by a licensed bank in Hong
account in Hong Kong; and
Kong, and have your name certified on the
•
show your account name, which must either
back by a person authorised by the bank.
be pre-printed on the cheque, or be endorsed
The name on the banker’s cashier order
on the back by a person authorised by the
must correspond with your name. If it is
bank. This account name must correspond
a joint application, the name on the back
with your name. If it is a joint application,
of the banker’s cashier order must be the
the account name must be the same as the
same as the first-named applicant’s name.
first-named applicant’s name.

Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant

  1. Tear off the Application Form, fold it once and lodge your completed Application Form (with cheque or banker’s cashier order attached) to one of the collection boxes at any of the following branches of:

Bank of China (Hong Kong) Limited

District Branch Name Address Hong Kong Shek Tong Tsui Branch 534 Queen’s Road West, Shek Tong Tsui, Hong Kong Island 409 Hennessy Road Branch 409-415 Hennessy Road, Wan Chai, Hong Kong Kowloon Mei Foo Mount Sterling Mall Shop N47-49, G/F, Mount Sterling Mall, Branch Mei Foo Sun Chuen, Kowloon Kowloon Plaza Branch Unit 1, Kowloon Plaza, 485 Castle Peak Road, Kowloon New Territories Tai Wai Branch 74-76 Tai Wai Road, Sha Tin, New Territories Castle Peak Road (Yuen Long) 162 Castle Peak Road, Yuen Long, Branch New Territories 5. Your Application Form can be lodged at these times: Tuesday, October 13, 2020 – 9:00 a.m. to 5:00 p.m. – Wednesday, October 14, 2020 9:00 a.m. to 5:00 p.m. – Thursday, October 15, 2020 9:00 a.m. to 5:00 p.m. Friday, October 16, 2020 – 9:00 a.m. to 12:00 noon 6. The latest time for lodging your application is 12:00 noon on Friday, October 16, 2020. The application lists will be opened between 11:45 a.m. to 12:00 noon on that day, subject only to the weather conditions, as described in “Effect of Bad Weather on the Opening of the Application Lists” in the “How to Apply for the Hong Kong Offer Shares” section of the Prospectus. The applications for the Hong Kong Offer Shares will commence on Tuesday, October 13, 2020 through Friday, October 16, 2020. The application monies (including the brokerage fees, SFC transaction levies and Stock Exchange trading fees) will be held by the receiving bank and on behalf of the Company after the closing of the application lists and the refund monies, if any, will be returned to the applicants without interest on or before Thursday, October 22, 2020. Investors should be aware that the dealings in the Shares on the Stock Exchange are expected to commence on Friday, October 23, 2020.

如 閣下欲以香港中央結算（代理人）有限公司（「香港結算代理人」）的名義登記將獲發行的香港發售股 份，並直接存入中央結算及交收系統（「中央結算系統」），以寄存於 閣下的中央結算系統投資者戶口 持有人股份戶口或 閣下指定的中央結算系統參與者股份戶口，請使用本表格

申請手續

  1. 使用下表計算 閣下應付的款項。 閣下申請認購的股數須至少為1,000股香港發售股份，並為下 表所列的其中一個數目，否則 閣下的申請將不獲受理。
先聲藥業集團有限公司
（每股香港發售股份13.70港元）
可供申請認購的香港發售股份數目及應繳款項		 先聲藥業集團有限公司
（每股香港發售股份13.70港元）
可供申請認購的香港發售股份數目及應繳款項		 先聲藥業集團有限公司
（每股香港發售股份13.70港元）
可供申請認購的香港發售股份數目及應繳款項		 先聲藥業集團有限公司
（每股香港發售股份13.70港元）
可供申請認購的香港發售股份數目及應繳款項
申請認購的
香港發售
股份數目
申請時
應繳款項
港元
 申請認購的
香港發售
股份數目
申請時
應繳款項
港元
 申請認購的
香港發售
股份數目
申請時
應繳款項
港元
 申請認購的
香港發售
股份數目
申請時
應繳款項
港元
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
10,000
15,000
13,838.06
27,676.11
41,514.17
55,352.22
69,190.28
83,028.33
96,866.39
110,704.44
124,542.50
138,380.55
207,570.83
 20,000
25,000
30,000
35,000
40,000
45,000
50,000
60,000
70,000
80,000
90,000
276,761.10
345,951.38
415,141.65
484,331.93
553,522.20
622,712.48
691,902.75
830,283.29
968,663.84
1,107,044.39
1,245,424.94
 100,000
200,000
300,000
400,000
500,000
600,000
700,000
800,000
900,000
1,000,000
2,000,000
1,383,805.49
2,767,610.98
4,151,416.47
5,535,221.96
6,919,027.45
8,302,832.94
9,686,638.43
11,070,443.92
12,454,249.41
13,838,054.90
27,676,109.80
樣		 3,000,000
4,000,000
5,000,000
6,000,000
7,000,000
8,000,000
9,000,000
10,000,000
13,029,000(1)
41,514,164.70
55,352,219.60
69,190,274.50
83,028,329.40
96,866,384.30
110,704,439.20
124,542,494.10
138,380,549.00
180,296,017.30
(1) 閣下可申請認購的香港發售股份最
高數目。
2.
閣下作為申請人，必須按照下列指示以英文正楷填妥表格，並於申請表格次頁簽署。只接納親筆
簽名（不得以個人印章代替）。
如 閣下透過中央結算系統投資者戶口持有人以外的指定中央結算系統參與者提出申請：
•
該指定中央結算系統參與者必須於表格蓋上公司印鑑（附有公司名稱），並在適當方格內填寫
參與者編號。
如 閣下以個人中央結算系統投資者戶口持有人名義提出申請：
•
表格須載有 閣下的姓名和香港身份證號碼。
•
須在適當方格內填寫 閣下的參與者編號。
如 閣下以聯名個人中央結算系統投資者戶口持有人名義提出申請：
•
表格須載有所有聯名投資者戶口持有人的姓名和香港身份證號碼；
•
須在適當方格內填寫 閣下的參與者編號。
如 閣下以公司中央結算系統投資者戶口持有人名義提出申請：
•
表格須載有 閣下的公司名稱和香港商業登記號碼；
•
須在適當方格內填寫 閣下的參與者編號並蓋上公司印鑑（附有公司名稱）。
中央結算系統參與者的資料（包括參與者編號及╱或附有公司名稱之公司印鑑）或其他類似事項如
有不確或遺漏，均可能導致 閣下的申請無效。
3.
閣下須將支票或銀行本票釘於表格上。每份香港發售股份申請須附一張獨立開出的支票或一張獨
立開出的銀行本票。支票或銀行本票必須符合以下所有規定，否則 閣下的申請將不獲受理：
Sample
支票必須：
 銀行本票必須：
•
為港元；
•
不得為期票；
•
註明抬頭人為「中國銀行（香港）代理人有限公司－先聲藥業公開發售」；
•
劃線註明「只准入抬頭人賬戶」；
•
從 閣下在香港的港元銀行賬戶中開出；及
•
顯示
閣下的賬戶名稱，而該賬戶名稱
必須已預印在支票上，或由有關銀行授
權的人士在支票背書。賬戶名稱必須
與
閣下姓名╱名稱相同。如屬聯名申
請，賬戶名稱必須與排名首位申請人的
姓名╱名稱相同。		 •
須由香港持牌銀行開出，並由有關銀
行授權的人士在銀行本票背面簽署核
證
閣下姓名╱名稱。銀行本票所示
姓名╱名稱須與
閣下姓名╱名稱相
同。如屬聯名申請，銀行本票背面所示
姓名╱名稱必須與排名首位申請人的姓
名╱名稱相同。

如 閣下欲以香港中央結算（代理人）有限公司（「香港結算代理人」）的名義登記將獲發行的香港發售股 份，並直接存入中央結算及交收系統（「中央結算系統」），以寄存於 閣下的中央結算系統投資者戶口 持有人股份戶口或 閣下指定的中央結算系統參與者股份戶口，請使用本表格

  1. 請撕下申請表格，對摺一次，然後將填妥的申請表格（連同支票或銀行本票）投入下列任何一家分 行特設的收集箱：

中國銀行（香港）有限公司

地區 分行名稱 地址 香港島 石塘咀分行 香港石塘咀皇后大道西534號 軒尼詩道409號分行 香港灣仔軒尼詩道409-415號 九龍 美孚萬事達廣場分行 九龍美孚新邨萬事達廣場地下N47-49號舖 九龍廣場分行 九龍青山道485號九龍廣場1號 新界 大圍分行 新界沙田大圍道74-76號 元朗青山道分行 新界元朗青山公路162號 5. 閣下可於下列時間遞交申請表格： 2020年10月13日（星期二）－上午九時正至下午五時正 2020年10月14日（星期三）－上午九時正至下午五時正 2020年10月15日（星期四）－上午九時正至下午五時正 2020年10月16日（星期五）－上午九時正至中午十二時正 6. 截止遞交申請的時間為2020年10月16日（星期五）中午十二時正。本公司將於當日上午十一時四十 五分至中午十二時正期間開始辦理申請登記，唯一會影響此時間的變化因素為當日的天氣情況（詳 見招股書「如何申請香港發售股份」一節「惡劣天氣對開始辦理申請登記的影響」）。 香港發售股份申請將會自2020年10月13日（星期二）起直至2020年10月16日（星期五）止。申請款 項（包括經紀佣金、證監會交易徵費及聯交所交易費）將由收款銀行於截止辦理申請登記後代表本 公司持有，且退款金額（如有）將於2020年10月22日（星期四）或之前不計利息退還予申請人。投 資者務請注意，預期股份將於2020年10月23日（星期五）於聯交所開始買賣。

Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant Simcere Pharmaceutical Group Limited 先聲藥業集團有限公司 (Incorporated in Hong Kong with limited liability) GLOBAL OFFERING Conditions of your application • undertake and confirm that you or the person(s) for whose benefit A. Who can apply you have made the application have not applied for or taken up, or 1. You and any person(s) for whose benefit you are applying must be indicated an interest for, and will not apply for or take up, or indicate 18 years of age or older and must have a Hong Kong address. an interest for, any Offer Shares under the International Offering nor 2. If you are a firm, the application must be in the individual participated in the International Offering; members’ names. • agree to disclose to the Company, the Hong Kong Share 3. The number of joint applicants may not exceed four. Registrar, receiving bank and the Relevant Persons any personal 4. If you are a body corporate, the application must be signed by a data which they may require about you and the person(s) for duly authorised officer, who must state his or her representative whose benefit you have made the application; capacity, and stamped with your corporation’s chop. • if the laws of any place outside Hong Kong apply to your 5. You must be outside the United States, not be a United States application, agree and warrant that you have complied with all Person (within the meaning of Regulation S under the U.S. such laws and none of the Company nor the Relevant Persons will Securities Act) or a person described in paragraph (h)(3) of Rule breach any law outside Hong Kong as a result of the acceptance 902 of Regulation S under the U.S. Securities Act and not be a of your offer to purchase, or any action arising from your rights legal or natural person of the PRC. and obligations under the terms and conditions contained in the 6. Unless permitted by the Listing Rules or any relevant waivers Prospectus and this Application Form; that have been granted by the Stock Exchange, you cannot apply • agree that once your application has been accepted, you may not for any Hong Kong Offer Shares if you are: rescind it because of an innocent misrepresentation; • an existing beneficial owner of shares in the Company and/ • agree that your application will be governed by the laws of Hong or any of its subsidiaries; Kong; • a Director or chief executive officer of the Company and/or • represent , warrant and undertake that (i) you understand any of its subsidiaries; that the Hong Kong Offer Shares have not been and will not • a close associate of any of the above; be registered under the U.S. Securities Act; and (ii) you and • a connected person of the Company or will become a any person for whose benefit you are applying for the Hong connected person of the Company immediately upon Kong Offer Shares are outside the United States (as defined in completion of the Global Offering; or Regulation S) or are a person described in paragraph (h)(3) of • have been allocated or have applied for or indicated an Rule 902 of Regulation S; interest in any Offer Shares under the International Offering. • warrant that the information you have provided is true and B. If you are a nominee accurate; You, as a nominee, may make more than one application for the Hong • agree to accept the Hong Kong Offer Shares applied for, or any Kong Offer Shares by: (i) giving electronic application instructions to lesser number allocated to you under the application; HKSCC via Central Clearing and Settlement System (“ CCASS ”) (if • authorise the Company to place the name of the HKSCC you are a CCASS Participant); or (ii) using a WHITE or YELLOW Nominees on the Company’s register of members as the holder(s) Application Form, and lodge more than one application in your own of any Hong Kong Offer Shares allocated to you, and the Company name on behalf of different beneficial owners. and/or its agents to deposit any share certificate(s) into CCASS and/or to send any refund cheque(s) to you or the first-named C. Effect of completing and submitting this Application Form applicant for joint application by ordinary post at your own risk to By completing and submitting this Application Form, you (and if you are the address stated on the application, unless you have fulfilled the joint applicants, each of you jointly and severally) for yourself or as an criteria set out in “Personal Collection” in the “How to Apply for agent or a nominee on behalf of each person for whom you act: the Hong Kong Offer Shares” section of the Prospectus to collect • undertake to execute all relevant documents and instruct and refund cheque(s) in person; authorise the Company and/or the Joint Global Coordinators (or • agree that the shares to be allotted shall be issued in the name of their agents or nominees), as agents of the Company, to execute any HKSCC Nominees and deposited directly into CCASS for credit documents for you and to do on your behalf all things necessary to to your investor participant stock account or the stock account of register any Hong Kong Offer Shares allocated to you in the name your designated CCASS Participant; of HKSCC Nominees as required by the Articles of Association; • agree that each of HKSCC and HKSCC Nominees reserves the • agree to comply with the Companies Ordinance (Chapter 622 right (1) not to accept any or part of such allotted shares issued of the Laws of Hong Kong), the Companies (Winding Up and in the name of HKSCC Nominees or not to accept such allotted Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of shares for deposit into CCASS; (2) to cause such allotted shares Hong Kong) and the Articles of Association;

  • agree that each of HKSCC and HKSCC Nominees reserves the right (1) not to accept any or part of such allotted shares issued in the name of HKSCC Nominees or not to accept such allotted shares for deposit into CCASS; (2) to cause such allotted shares to be withdrawn from CCASS and issued in your name at your own risk and costs; and (3) to cause such allotted shares to be issued in your name (or, if you are a joint applicant, to the firstnamed applicant) and in such a case, to post the certificates for such allotted shares at your own risk to the address on your application form by ordinary post or to make available the same for your collection;

  • confirm that you have read the terms and conditions and application procedures set out in the Prospectus and in this Application Form and agree to be bound by them;

  • confirm that you have received and read the Prospectus and have only relied on the information and representations contained in the Prospectus in making your application and will not rely on any other information or representations except those in any supplement to the Prospectus;

  • agree that each of HKSCC and HKSCC Nominees may adjust the number of allotted shares issued in the name of HKSCC Nominees;

  • confirm that you are aware of the restrictions on the Global Offering in the Prospectus;

  • agree that none of the Company, the Joint Sponsors, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Underwriters, their respective directors, officers, employees, partners, agents, advisers and any other parties involved in the Global Offering (the “ Relevant Persons ”) and the White Form eIPO Service Provider is or will be liable for any information and representations not in the Prospectus (and any supplement to it);

  • agree that neither HKSCC nor HKSCC Nominees shall have any liability for the information and representations not so contained in the Prospectus and this Application Form;

  • agree that neither HKSCC nor HKSCC Nominees shall be liable to you in any way;

Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant

Kong Public Offering shall not exceed 26,056,000 Shares, representing approximately 10% of the Offer Shares initially available under the Global Offering, increasing the total number of Offer Shares available under the Hong Kong Public Offering to 52,114,000 Shares, representing approximately 20% of the Offer Shares and the final Offer Price shall be fixed at the low-end of the indicative Offer Price range (i.e. HK$12.10 per Offer Share) stated in the Prospectus.

• understand that, in accordance with Guidance Letter HKEXKong Public Offering shall not exceed 26,056,000 Shares, representing GL91-18 issued by the Stock Exchange, where the International Offer approximately 10% of the Offer Shares initially available under Shares are undersubscribed and the Hong Kong Offer Shares are the Global Offering, increasing the total number of Offer Shares oversubscribed irrespective of the number of times, up to 26,056,000 available under the Hong Kong Public Offering to 52,114,000 Shares, Offer Shares may be reallocated to the Hong Kong Public Offering representing approximately 20% of the Offer Shares and the final Offer from the International Offering, so that the total number of the Shares Price shall be fixed at the low-end of the indicative Offer Price range available under the Hong Kong Public Offer will be increased to (i.e. HK$12.10 per Offer Share) stated in the Prospectus. 52,114,000 Offer Shares, representing approximately 20% of the number of the Offer Shares initially available under the Global If your application for Hong Kong Offer Shares is successful (in Offering (before any exercise of the Over-allotment Option), and whole or in part) the final Offer Price shall be fixed at the low-end of the indicative If your application is wholly or partially successful, your share Offer Price range (i.e. HK$12.10 per Offer Share) as stated in certificate(s) (subject to their becoming valid certificates of title the Prospectus. Further details of the reallocation are stated in the provided that the Hong Kong Public Offering has become unconditional paragraph headed “Structure of the Global Offering – The Hong and not having been terminated at 8:00 a.m. on Friday, October 23, Kong Public Offering – Reallocation” of the Prospectus; 2020) will be issued in the name of HKSCC Nominees and deposited • declare and represent that this is the only application made and directly into CCASS for credit to your CCASS Investor Participant the only application intended by you to be made to benefit you or stock account or the stock account of your designated CCASS the person for whose benefit you are applying; Participant as instructed by you in your Application Form on Thursday, • understand that the Company and the Joint Global Coordinators October 22, 2020 or, in the event of a contingency, on any other date as will rely on your declarations and representations in deciding shall be determined by HKSCC or HKSCC Nominees. whether or not to make any allotment of any of the Hong Kong • If you are applying through a designated CCASS Participant Offer Shares to you and that you may be prosecuted for making a (other than a CCASS Investor Participant): For Hong Kong Offer false declaration; Shares credited to the stock account of your designated CCASS • (if the application is made for your own benefit) warrant that no other Participant (other than a CCASS Investor Participant), you can application has been or will be made for your benefit on a WHITE check the number of Hong Kong Offer Shares allotted to you or YELLOW Application Form or by giving electronic application with that CCASS Participant. instructions to HKSCC or to the White Form eIPO Service Provider • If you are applying as a CCASS Investor Participant: The by you or by any one as your agent or by any other person; and Company expects to publish the results of CCASS Investor • (if you are making the application as an agent for the benefit of Participants’ applications together with the results of the another person) warrant that (i) no other application has been or Hong Kong Public Offering on the website of the Stock will be made by you as agent for or for the benefit of that person Exchange at www.hkexnews.hk and the Company’s website at or by that person or by any other person as agent for that person www.simcere.com on Thursday, October 22, 2020. You should on a WHITE or YELLOW Application Form or by giving check the announcement published by the Company and report electronic application instructions to HKSCC; and (ii) you have due any discrepancies to HKSCC before 5:00 p.m. on Thursday, authority to sign the Application Form or give electronic application October 22, 2020 or such other date as shall be determined by instructions on behalf of that other person as their agent. HKSCC or HKSCC Nominees. Immediately after the credit of the Hong Kong Offer Shares to your stock account you can D. Power of attorney check your new account balance via the CCASS Phone System If your application is made through an authorised attorney, the and CCASS Internet System (under the procedures contained Company and the Joint Global Coordinators may accept or reject your in HKSCC’s “An Operating Guide for Investor Participants” in application at their discretion, and on any conditions they think fit, effect from time to time). HKSCC will also make available to you including evidence of the attorney’s authority. an activity statement showing the number of Hong Kong Offer Shares credited to your stock account. Determination of Offer Price and Allocation of Hong Kong Offer No receipt will be issued for application money paid. The Company Shares will not issue temporary documents of title. The Offer Price is expected to be fixed on or around Friday, October 16, 2020. Applicants are required to pay the maximum Offer Price of Refund of your money HK$13.70 for each Hong Kong Offer Share together with 1% brokerage, If you do not receive any Hong Kong Offer Shares or if your 0.0027% SFC transaction levy and 0.005% Stock Exchange trading fee. application is accepted only in part, the Company will refund to you If the Offer Price is not agreed among the Company and the Joint Global your application monies (including the related 1% brokerage, 0.0027% Coordinators (for themselves and on behalf of the Underwriters) on or SFC transaction levy and 0.005% Stock Exchange trading fee) without before Thursday, October 22, 2020, the Global Offering will not proceed. interest. If the Offer Price is less than the maximum Offer Price, the Company will refund to you the surplus application monies (including Applications for Hong Kong Offer Shares will not be processed and the related 1% brokerage, 0.0027% SFC transaction levy and 0.005% no allotment of any Hong Kong Offer Shares will be made until the Stock Exchange trading fee) without interest. application lists close. The refund procedures are stated in the “Despatch/Collection of Share The Company expects to announce the final Offer Price, the Certificates and Refund Monies” in the “How to Apply for the Hong indication of the level of interest in the International Offering, Kong Offer Shares” section of the Prospectus. the level of applications under the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares Effect of the Information You Give to Computershare Hong Kong on Thursday, October 22, 2020 on the website of the Stock Exchange at Investor Services Limited www.hkexnews.hk and the Company’s website at www.simcere.com . Computershare Hong Kong Investor Services Limited and its Results of allocations and the Hong Kong Identity Card/passport/Hong related bodies corporate, directors, officers, employees and agents Kong business registration numbers of successful applicants (where (“ Representatives ”) expressly disclaim and exclude to the maximum applicable) will be available on the above websites. extent permitted by law any liability for any loss or damage suffered

Computershare Hong Kong Investor Services Limited and its related bodies corporate, directors, officers, employees and agents (“ Representatives ”) expressly disclaim and exclude to the maximum extent permitted by law any liability for any loss or damage suffered or incurred by the applicant or any other person or entity however caused relating in any way to, or connected with, any information provided by or on behalf of the applicant on or in connection with this document or any services provided hereunder, or any other written or oral communication provided by or on behalf of the applicant in connection with this document or any services provided hereunder. This includes, without limitation, any errors or omissions in such information however caused, or the Representatives or any other person or entity placing any reliance on such information or any documentation, image, recording or reproduction of such information, or its accuracy, completeness, currency or reliability.

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to adjustment as described in the section headed “Structure of the Global Offering – The Hong Kong Public Offering – Reallocation” in the Prospectus. In particular, the Joint Global Coordinators may reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Guidance Letter HKEx-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to Practice Note 18 of the Listing Rules, the number of Offer Shares that may be reallocated from the International Offering to the Hong

  • 如 閣下欲以香港中央結算（代理人）有限公司（「香港結算代理人」）的名義登記將獲發行的香港發售股 份，並直接存入中央結算及交收系統（「中央結算系統」），以寄存於 閣下的中央結算系統投資者戶口 持有人股份戶口或 閣下指定的中央結算系統參與者股份戶口，請使用本表格 Simcere Pharmaceutical Group Limited 先聲藥業集團有限公司 （於香港註冊成立的有限公司） 全球發售

  • 申請條件 ‧ 承諾 及 確認 閣下或 閣下為其利益提出申請的人士並 甲、 可提出申請的人士 無申請或接納或表示有意認購（亦不會申請或接納或表 1. 閣下及 閣下為其利益提出申請的人士必須年滿18歲並 示有意認購）國際發售的任何發售股份，也沒有參與國 有香港地址。 際發售；

    1. 如 閣下為商號，申請須以個別成員名義提出。 ‧ 同意 在本公司、香港股份過戶登記處、收款銀行及有關 3. 聯名申請人不得超過四名。 人士提出要求時，向彼等披露其所要求提供有關 閣下 4. 如 閣下為法人團體，申請須經獲正式授權人員簽署， 及 閣下為其利益提出申請的人士的個人資料； 並註明其所屬代表身份及蓋上公司印鑑。 ‧ 若香港境外任何地方的法例適用於 閣下的申請，則 同
    1. 閣下必須身處美國境外，並非美籍人士（定義見美國證 意 及 保證 閣下已遵守所有有關法例，且本公司及有關 券法S規例）或屬美國證券法S規例第902條第(h)(3)段所 人士概不會因接納 閣下的購買要約，或 閣下在招股 述人士，亦非中國法人或自然人。 書及本申請表格所載的條款及條件項下的權利及責任所
    1. 除上市規則或聯交所已授予的任何相關豁免批准外，下 引致的任何行動，而違反香港境外的任何法例； 列人士概不得申請認購任何香港發售股份： ‧ 同意 閣下的申請一經接納，即不得因無意的失實陳述 ‧ 本公司及╱或其任何附屬公司股份的現有實益擁 而撤銷； 有人； ‧ 同意 閣下的申請受香港法例規管；

  • ‧ 本公司及╱或其任何附屬公司的董事或首席執行官； ‧ 聲明 、 保證 及 承諾 ：(i) 閣下明白香港發售股份不曾亦 ‧ 上述任何人士的緊密聯繫人； 不會根據美國證券法登記；及(ii) 閣下及 閣下為其

  • ‧ 本公司的關連人士或緊隨全球發售完成後成為本公 利益申請香港發售股份的人士均身處美國境外（定義見

  • 司關連人士的人士；或 S規例），或屬S規例第902條第(h)(3)段所述的人士；

  • ‧ 已獲分配或已申請或表示有意申請國際發售的任何 ‧ 保證 閣下提供的資料真實及準確； 發售股份的人士。 ‧ 同意 接納所申請數目或根據申請分配予 閣下但數目較

  • 乙、 如 閣下為代名人 少的香港發售股份； 閣下作為代名人可提交超過一份香港發售股份申請，方法 ‧ 授權 本公司將香港結算代理人的名稱列入本公司股東名 是：(i)透過中央結算及交收系統（「 中央結算系統 」）向香港 冊，作為 閣下獲分配的任何香港發售股份的持有人， 結算發出電子認購指示（如 閣下為中央結算系統參與者）； 並授權本公司及╱或其代理將任何股票存入中央結算 或(ii)使用 白色 或 黃色 申請表格以自身名義代表不同的實益擁 系統及╱或以普通郵遞方式按申請所示地址向 閣下 有人提交超過一份申請。 或聯名申請的排名首位申請人寄發任何退款支票，郵誤 風險由 閣下承擔，除非 閣下已符合招股書「如何申

  • 丙、 填交本申請表格的效用 請香港發售股份」一節「親身領取」所載條件親身領取

  • 閣下填妥並遞交本申請表格，即表示 閣下（如屬聯名申請 退款支票；

  • 人，即各人共同及個別）代表 閣下本身，或作為 閣下代 ‧ 同意 獲配發的股份是以香港結算代理人的名義發行，並

  • 其行事的每位人士的代理或代名人： ‧ 承諾 簽立所有相關文件，並指示及授權本公司及╱或 直接存入中央結算系統，以便寄存於 閣下的投資者戶 口持有人股份戶口或 閣下的指定中央結算系統參與者

  • 聯席全球協調人（或彼等的代理或代名人）（作為本公司 股份戶口；

  • 代理），為按照組織章程細則的規定將 閣下獲分配的 任何香港發售股份以香港結算代理人的名義登記而代 ‧ 同意 香港結算及香港結算代理人各自保留權利(1)不接納 以香港結算代理人名義發行的該等獲配發的任何或部分

  • 表 閣下簽立任何文件及代 閣下進行一切必要事宜；

  • ‧ 同意 遵守香港法例第622章公司條例、香港法例第32章 股份，或不接納該等獲配發的股份存入中央結算系統； 公司（清盤及雜項條文）條例及組織章程細則； (2)促使該等獲配發的股份從中央結算系統提取，並轉

  • ‧ 確認 閣下已細閱招股書及本申請表格所載的條款及條 入 閣下名下，有關風險及費用概由 閣下自行承擔； 件以及申請程序，並同意受其約束； 及(3)促使該等獲配發的股份以 閣下名義發行（或如屬

  • ‧ 確認 閣下已接獲及細閱招股書，提出申請時也僅依據 聯名申請人，則以排名首位申請人的名義發行），而在 招股書載列的資料及陳述，而除招股書任何補充文件 此情況下，會以普通郵遞方式將該等獲配發股份的股票 外，不會依賴任何其他資料或陳述； 寄往 閣下在申請表格上所示地址（郵誤風險概由 閣

  • ‧ 下自行承擔）或提供該等股票予 閣下領取；

  • ‧ 確認 閣下知悉招股書內有關全球發售的限制；

  • ‧ 同意 香港結算及香港結算代理人均可調整獲配發以香港 結算代理人名義發行的股份數目；

  • ‧ 同意 本公司、聯席保薦人、聯席全球協調人、聯席賬簿 管理人、聯席牽頭經辦人、包銷商、彼等各自的董事、 高級職員、僱員、合夥人、代理、顧問及參與全球發售 的任何其他各方（「 有關人士 」）及 白表eIPO 服務供應商 現時及日後均無須對並非載於招股書（及其任何補充文 件）的任何資料及陳述負責；

  • ‧ 同意 香港結算及香港結算代理人對招股書及本申請表格 未有載列的資料及陳述概不負責；

  • ‧ 同意 香港結算及香港結算代理人概不以任何方式對 閣 下負責；

如 閣下欲以香港中央結算（代理人）有限公司（「香港結算代理人」）的名義登記將獲發行的香港發售股 份，並直接存入中央結算及交收系統（「中央結算系統」），以寄存於 閣下的中央結算系統投資者戶口 持有人股份戶口或 閣下指定的中央結算系統參與者股份戶口，請使用本表格

約10%，使香港公開發售項下可供認購的發售股份總數增至10%，使香港公開發售項下可供認購的發售股份總數增至，使香港公開發售項下可供認購的發售股份總數增至 52,114,000股，佔發售股份約20%，及最終發售價須為招股股，佔發售股份約20%，及最終發售價須為招股20%，及最終發售價須為招股，及最終發售價須為招股 書所載的指示性發售價範圍的低位數（即每股發售股份12.1012.10 港元）。

‧ 明白 根據聯交所發出的指引信HKEX-GL91-18，當國際 約10%，使香港公開發售項下可供認購的發售股份總數增至10%，使香港公開發售項下可供認購的發售股份總數增至，使香港公開發售項下可供認購的發售股份總數增至 發售股份認購不足而香港發售股份出現超額認購（不論 52,114,000股，佔發售股份約20%，及最終發售價須為招股股，佔發售股份約20%，及最終發售價須為招股20%，及最終發售價須為招股，及最終發售價須為招股 多少倍），最多26,056,000股發售股份可由國際發售重新 書所載的指示性發售價範圍的低位數（即每股發售股份12.1012.10 配發至香港公開發售，香港公開發售可供認購股份總數 港元）。 將從而增加至52,114,000股發售股份，相當於全球發售 初步提呈認購的發售股份數目約20%（於行使任何超額 如 閣下成功申請認購香港發售股份（全部或部分） 配股權前），而最終發售價將定於招股書所述的指示性 如 閣下的申請全部或部分獲接納， 閣下的股票（前提是 發售價範圍的低位數（即每股發售股份12.10港元）。重 到2020年10月23日（星期五）上午八時正香港公開發售成為 新分配的進一步詳情載於招股書「全球發售的架構－香 無條件而並無終止，股票成為有效的所有權證明）將以香港 港公開發售－重新分配」一段； 結算代理人名義發出，並按 閣下在申請表格的指示於2020 ‧ 聲明 及 陳述 此乃 閣下為本身或為其利益提出申請的人 年10月22日（星期四）或在特別情況下由香港結算或香港結 士所提出及擬提出的唯一申請； 算代理人指定的任何其他日期直接存入中央結算系統，記 ‧ 明白 本公司及聯席全球協調人將依據 閣下的聲明及陳 入 閣下的中央結算系統投資者戶口持有人股份戶口或 閣 述而決定是否向 閣下分配任何香港發售股份， 閣下 下指定的中央結算系統參與者股份戶口。 ‧ 如 閣下透過中央結算系統投資者戶口持有人以外的指 如作出虛假聲明，可能會被檢控； ‧ （如本申請是為 閣下本身利益提出） 保證 閣下或作 定中央結算系統參與者提出申請：香港發售股份將存 入 閣下指定的中央結算系統參與者（中央結算系統投 為 閣下代理的任何人士或任何其他人士不曾亦不會 資者戶口持有人除外）股份戶口， 閣下可向該中央結 為 閣下利益而以 白色 或 黃色 申請表格或向香港結算或 算系統參與者查詢 閣下獲配發的香港發售股份數目。 向 白表eIPO 服務供應商發出電子認購指示而提出其他 ‧ 如 閣下以中央結算系統投資者戶口持有人身份提出申 申請；及 ‧ （如 閣下作為代理為另一人士的利益提出申請） 保證 請：本公司預期於2020年10月22日（星期四）在聯交所 網站 www.hkexnews.hk 及本公司網站 www.simcere.com (i) 閣下（作為代理或為該人士利益）或該人士或任何 刊登中央結算系統投資者戶口持有人的申請結果及香港 其他作為該人士代理的人士不曾亦不會以 白色 或 黃色 申 公開發售的結果。 閣下應查閱本公司刊發的公告，如 請表格或向香港結算發出電子認購指示而提出其他申 有任何資料不符，請於2020年10月22日（星期四）或香 請；及(ii) 閣下獲正式授權作為該人士的代理代為簽 港結算或香港結算代理人釐定的任何其他日期下午五時 署本申請表格或發出電子認購指示。 正前知會香港結算。緊隨香港發售股份存入 閣下的 股份戶口後， 閣下即可透過「結算通」電話系統及中 丁、 授權書 央結算系統互聯網系統（根據香港結算不時生效的「投 如 閣下透過授權代理人提出申請，本公司及聯席全球協調 資者戶口操作簡介」所載程序）查詢 閣下的新戶口結 人可按其認為合適的條件（包括出示獲授權證明）酌情接納 餘。香港結算亦將向 閣下提供一份活動結單，列出存 或拒絕 閣下的申請。 入 閣下股份戶口的香港發售股份數目。 申請時繳付的款項不會發出收據。本公司亦不會發出臨時所 釐定發售價及香港發售股份的分配 有權文件。 預期發售價於2020年10月16日（星期五）或前後釐定。申請 人須繳付每股香港發售股份13.70港元的最高發售價，另加 退回款項 1%經紀佣金、0.0027%證監會交易徵費及0.005%聯交所交易 若 閣下未獲分配任何香港發售股份或申請僅部分獲接納， 費。倘若本公司與聯席全球協調人（為其本身及代表包銷商） 本公司將不計利息退回 閣下的申請股款（包括相關的1%經 並無於2020年10月22日（星期四）或之前協定發售價，全球 紀佣金、0.0027%證監會交易徵費及0.005%聯交所交易費）。 發售將不會進行。 如發售價低於最高發售價，本公司將不計利息退回多收申請 股款（包括相關的1%經紀佣金、0.0027%證監會交易徵費及 截止登記認購申請前，概不處理香港發售股份的申請或配發 0.005%聯交所交易費）。 任何香港發售股份。 有關退款程序載於招股書「如何申請香港發售股份」一節「寄 本公司預期於2020年10月22日（星期四）在聯交所網站 發╱領取股票及退回股款」。 www.hkexnews.hk 及本公司網站 www.simcere.com 公佈最終 發售價、國際發售踴躍程度、香港公開發售申請水平及香港 閣下提供給香港中央證券登記有限公司的資料的有關影響 發售股份分配基準。分配結果以及獲接納申請人的香港身份 香港中央證券登記有限公司和其有關聯的法人團體、董事、 證╱護照╱香港商業登記號碼（如適用）亦將於上述網站公 高級職員、僱員及代理人（「 代表 」）在法律所容許的最大限 佈。 度內明確卸棄及免除在任何方面與申請人或代表申請人在此

閣下提供給香港中央證券登記有限公司的資料的有關影響 香港中央證券登記有限公司和其有關聯的法人團體、董事、 高級職員、僱員及代理人（「 代表 」）在法律所容許的最大限 度內明確卸棄及免除在任何方面與申請人或代表申請人在此 文件提供的或與此文件或在此文件下提供的任何服務相關的 任何資料，或任何申請人或代表申請人提供與此文件或在此 文件下提供的任何服務相關的任何其他書面或口頭通訊，有 關或相關由申請人或任何其他人士或實體所遭受或招致不論 如何造成的任何損失或損害的任何法律責任。此包括，但不 限於，該等資料中不論如何造成的任何錯誤或遺漏，或代表 或任何其他人士或實體對該等資料或任何該等資料的文件記 錄、影像、記錄或複製品作出的任何依據，或其準確性、完 整性、合時性或可靠性。

在香港公開發售與國際發售之間分配發售股份將受招股書 「全球發售的架構－香港公開發售－重新分配」一節所述調 整規限。特別是，聯席全球協調人可將發售股份由國際發售 重新分配至香港公開發售，以滿足根據香港公開發售作出 的有效申請。根據聯交所發出的指引信HKEx-GL91-18，倘 有關重新分配並非根據上市規則第18項應用指引作出，則 可由國際發售重新分配至香港公開發售的發售股份數目不 得超過26,056,000股，佔全球發售下初步可供認購發售股份

Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant

Personal Data

3. Transfer of personal data

Personal Information Collection Statement

This Personal Information Collection Statement informs the Personal data held by the Company and its Hong Kong applicant for, and holder of, Hong Kong Offer Shares, of the Share Registrar relating to the securities holders will be kept policies and practices of the Company and its Hong Kong confidential but the Company and its Hong Kong Share Share Registrar in relation to personal data and the Personal Registrar may, to the extent necessary for achieving any of Data (Privacy) Ordinance (Cap. 486) (the “ Ordinance ”). the above purposes, disclose, obtain or transfer (whether 1. Reasons for the collection of your personal data within or outside Hong Kong) the personal data to, from or It is necessary for applicants and registered holders of with any of the following: securities to supply correct personal data to the Company or • the Company’s appointed agents such as financial its agents and the Hong Kong Share Registrar when applying advisers, receiving bankers and overseas principal for securities or transferring securities into or out of their share registrar; names or in procuring the services of the Hong Kong Share • where applicants for securities request a deposit into Registrar. CCASS, HKSCC or HKSCC Nominees, who will Failure to supply the requested data may result in your use the personal data for the purposes of operating application for securities being rejected, or in delay or the CCASS; inability of the Company or its Hong Kong Share Registrar • any agents, contractors or third-party service providers to effect transfers or otherwise render their services. It may who offer administrative, telecommunications, also prevent or delay registration or transfers of the Hong computer, payment or other services to the Company or Kong Offer Shares which you have successfully applied the Hong Kong Share Registrar in connection with their for and/or the dispatch of share certificate(s) and/or refund respective business operation; cheque(s) to which you are entitled. • the Stock Exchange, the SFC and any other statutory It is important that securities holders inform the Company regulatory or governmental bodies or otherwise as and the Hong Kong Share Registrar immediately of any required by laws, rules or regulations; and inaccuracies in the personal data supplied. • any persons or institutions with which the securities’ 2. Purposes holders have or propose to have dealings, such as The personal data of the securities holders may be used, their bankers, solicitors, accountants or stockbrokers held, processed, and/or stored (by whatever means) for the etc. following purposes: • processing your application and refund cheque, where 4. Retention of personal data applicable, verification of compliance with the terms The Company and its Hong Kong Share Registrar will keep and application procedures set out in this Application the personal data of the applicants and holders of securities Form and the Prospectus and announcing results of allocation of the Hong Kong Offer Shares; for as long as necessary to fulfil the purposes for which • compliance with applicable laws and regulations in the personal data were collected. Personal data which is no Hong Kong and elsewhere; longer required will be destroyed or dealt with in accordance • registering new issues or transfers into or out of with the Ordinance. the names of securities’ holders including, where applicable, HKSCC Nominees; 5. Access to and correction of personal data • maintaining or updating the register of securities’ Securities holders have the right to ascertain whether the holders of the Company; Company or the Hong Kong Share Registrar hold their • verifying securities holders’ identities; personal data, to obtain a copy of that data, and to correct • establishing benefit entitlements of securities’ holders any data that is inaccurate. The Company and the Hong of the Company, such as dividends, rights issues, bonus Kong Share Registrar have the right to charge a reasonable issues, etc.;

Securities holders have the right to ascertain whether the Company or the Hong Kong Share Registrar hold their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. The Company and the Hong Kong Share Registrar have the right to charge a reasonable fee for the processing of such requests.

  • distributing communications from the Company and its subsidiaries;

All requests for access to data or correction of data should be addressed to us, at our registered address disclosed in the “Corporate Information” section of the Prospectus or as notified from time to time, for the attention of the company secretary, or our Hong Kong Share Registrar for the attention of the privacy compliance officer.

  • compiling statistical information and securities’ holders profiles;

  • disclosing relevant information to facilitate claims on entitlements; and

  • any other incidental or associated purposes relating to the above and/or to enable the Company and the Hong Kong Share Registrar to discharge their obligations to securities’ holders and/or regulators and/or any other purposes to which the securities’ holders may from time to time agree.

By signing an Application Form or by giving electronic application instructions to HKSCC, you agree to all of the above.

如 閣下欲以香港中央結算（代理人）有限公司（「香港結算代理人」）的名義登記將獲發行的香港發售股 份，並直接存入中央結算及交收系統（「中央結算系統」），以寄存於 閣下的中央結算系統投資者戶口 持有人股份戶口或 閣下指定的中央結算系統參與者股份戶口，請使用本表格

個人資料

3. 轉交個人資料 本公司及其香港股份過戶登記處所持有關證券持有 人的個人資料將會保密，但本公司及其香港股份過 戶登記處可以在為達到上述任何目的之必要情況 下，向下列任何人士披露、獲取或轉交（無論在香 港境內或境外）有關個人資料：

個人資料收集聲明

此項個人資料收集聲明是向香港發售股份的申請人 本公司及其香港股份過戶登記處所持有關證券持有 和持有人說明有關本公司及其香港股份過戶登記處 人的個人資料將會保密，但本公司及其香港股份過 有關個人資料和第486章《個人資料（私隱）條例》 戶登記處可以在為達到上述任何目的之必要情況 （「 條例 」）方面的政策和慣例。 下，向下列任何人士披露、獲取或轉交（無論在香 港境內或境外）有關個人資料： 1. 收集 閣下個人資料的原因 • 本公司委任的代理人，例如財務顧問、收款銀 證券申請人及登記持有人以本身名義申請證券或轉 行和主要海外股份過戶登記分處； 讓或受讓證券時或尋求香港股份過戶登記處的服務 • （如證券申請人要求將證券存於中央結算系統） 時，必須向本公司或其代理人及香港股份過戶登記 香港結算或香港結算代理人；彼等將會就中央 處提供準確個人資料。 結算系統的運作使用有關個人資料； 未能提供所要求的資料可能導致 閣下申請證券被 • 向本公司或香港股份過戶登記處提供與其各自 拒或延遲，或本公司或其香港股份過戶登記處無法 業務營運有關的行政、電訊、電腦、付款或其 落實轉讓或提供服務。此舉也可能妨礙或延遲登記 他服務的任何代理人、承包商或第三方服務供 或轉讓 閣下成功申請的香港發售股份及╱或寄 應商； 發 閣下應得的股票及╱或退款支票。 • 聯交所、證監會及任何其他法定監管機關或政 府部門或遵照其他法例、規則或法規；及 證券持有人所提供的個人資料如有任何錯誤，須立 • 證券持有人與其進行或擬進行交易的任何人士 即通知本公司及香港股份過戶登記處。 或機構，例如彼等的銀行、律師、會計師或股 2. 目的 票經紀等。 證券持有人的個人資料可被採用及以任何方式持 有、處理及╱或保存，以作下列用途： 4. 個人資料的保留 • 處理 閣下的申請及退款支票（如適用）、核實 本公司及其香港股份過戶登記處將按收集個人資料 是否符合本申請表格及招股書載列的條款和申 所需的用途保留證券申請人及持有人的個人資料。 請程序以及公佈香港發售股份的分配結果； 無需保留的個人資料將會根據條例銷毀或處理。 • 遵守香港及其他地區的適用法律及法規； • 以證券持有人（包括香港結算代理人（如適 5. 查閱和更正個人資料 用））的名義登記新發行證券或轉讓或受讓證 證券持有人有權確定本公司或香港股份過戶登記處 券； 是否持有其個人資料，並有權索取有關該資料的副 • 存置或更新本公司證券持有人的名冊； 本並更正任何不準確資料。本公司和香港股份過戶 • 核實證券持有人的身份； 登記處有權就處理任何查閱資料的要求收取合理費 • 確定本公司證券持有人的受益權利，例如股 用。 息、供股和紅股等；

  • 分發本公司及其附屬公司的通訊；

所有查閱資料或更正資料的要求應按招股書「公司 資料」一節所披露或不時通知的本公司註冊地址送 交公司秘書，或向本公司的香港股份過戶登記處的 個人資料私隱事務主任提出。

  • 編製統計數據和證券持有人資料；

  • 披露有關資料以便就權益索償；及

  • 與上述有關的任何其他附帶或相關目的及╱或 使本公司及香港股份過戶登記處能履行對證券 持有人及╱或監管機構承擔的責任及╱或證券 持有人不時同意的任何其他目的。

閣下簽署申請表格或向香港結算發出電子認購指 示，即表示同意上述各項。

More from Simcere Pharmaceutical Group Limited

Transaction in Own Shares 2026
May 22
Report Publication Announcement 2026
May 21
Report Publication Announcement 2026
May 21
Proxy Solicitation & Information Statement 2026
May 21
Proxy Solicitation & Information Statement 2026
May 21
Proxy Solicitation & Information Statement 2026
May 21
Transaction in Own Shares 2026
May 21
Transaction in Own Shares 2026
May 20
Transaction in Own Shares 2026
May 19
Transaction in Own Shares 2026
May 19
View all filings →